Spruce Biosciences Inc expected to post a loss of 39 cents a share - Earnings Preview

Spruce Biosciences

12/03/2024 11:04

* Spruce Biosciences Inc  SPRB.OQ   SPRB.O  is expected
to show a
rise in quarterly revenue when it reports  results on March 14
(estimated) for the period ending December 31 2023
    * The South San Francisco California-based  company is
expected to
report revenue of $1.4 million, according to the mean estimate
from 7 analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Spruce Biosciences Inc
is for
a loss of 39 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 7 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Spruce
Biosciences Inc is $9.00​, above​ its last closing price
of $5.12. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.36       -0.35      -0.30     Beat    15.1
 Jun. 30 2023  -0.39       -0.39      -0.32     Beat    18.4
 Mar. 31 2023  -0.33       -0.36      -0.40     Missed  -10.4​
 Dec. 31 2022  -0.56       -0.53      -0.47     Beat    11.3
 ​​Sep.        -0.54       -0.53      -0.48     Beat    10.3
 30 2022                                                
 Jun. 30 2022  -0.53       -0.52      -0.51     Beat    2.9​
 Mar. 31 2022  -0.46       -0.46      -0.50     Missed  -9.1
 Dec. 31 2021  -0.54       -0.54      -0.39     Beat    27.8
 This summary was machine generated March 12 at 11:04 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)